rupiya.io
⠋Loading...
0%
❯ Scanning sector trends...
Onesource Specialty Pharma Ltd is a Biotechnology company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Onesource Specialty Pharma Ltd makes money through Technology services, Digital transformation projects, Maintenance and managed services in Biotechnology. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Create a free account to view momentum, moving averages, and delivery signals.
Upgrade to view volatility, drawdown, factor, and risk metrics.
| Period | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Sales | ₹21 Cr | ₹128 Cr | ₹39 Cr | ||
| Expenses | ₹93 Cr | ₹132 Cr | ₹199 Cr | ||
| Operating Profit | ₹-71 Cr | ₹-4 Cr | ₹-161 Cr | ||
| OPM % | -334.0% | -3.0% | -415.0% | ||
| Other Income | ₹1 Cr | ₹-128 Cr | ₹-526 Cr | ||
| Depreciation | ₹34 Cr | ₹53 Cr | ₹66 Cr | ||
| Interest | ₹16 Cr | ₹46 Cr | ₹48 Cr | ||
| Profit Before Tax | ₹-121 Cr | ₹-231 Cr | ₹-800 Cr | ||
| Tax | ₹-121 Cr | ₹-231 Cr | ₹-800 Cr | ||
| Net Profit | ₹-121 Cr | ₹-231 Cr | ₹-800 Cr | ||
| EPS (₹) | 0.0 | 0.0 | 0.0 | ||
| Dividend Payout % | 0% | 0% | 0% |
Register free to see 2 more years.
| Quarter | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹34 Cr | ₹56 Cr | ₹73 Cr | ₹292 Cr | ||||||
| Expenses | ₹72 Cr | ₹67 Cr | ₹76 Cr | ₹228 Cr | ||||||
| Operating Profit | ₹-39 Cr | ₹-11 Cr | ₹-3 Cr | ₹64 Cr | ||||||
| OPM % | -114.2% | -18.7% | -3.8% | 22.0% | ||||||
| Depreciation | ₹18 Cr | ₹20 Cr | ₹20 Cr | ₹68 Cr | ||||||
| Interest | ₹25 Cr | ₹26 Cr | ₹20 Cr | ₹42 Cr | ||||||
| Net Profit | ₹-114 Cr | ₹-130 Cr | ₹-40 Cr | ₹-6 Cr | ||||||
| EPS (₹) | 0.0 | 0.0 | 0.0 | 0.0 |
Register free to see 6 more quarters.
| Period | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹2 Cr | ₹3 Cr | ₹4 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹774 Cr | ₹1,009 Cr | ₹781 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹386 Cr | ₹1,182 Cr | ₹864 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹96 Cr | ₹248 Cr | ₹365 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹1,258 Cr | ₹2,442 Cr | ₹2,015 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹633 Cr | ₹1,231 Cr | ₹1,361 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹0 Cr | ₹0 Cr | ₹4 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹195 Cr | ₹722 Cr | ₹314 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹1,258 Cr | ₹2,442 Cr | ₹2,015 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Register free to see 2 more years.
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| Mar 2022 | ₹-118 Cr | ₹-207 Cr | ₹381 Cr | — |
| Mar 2023 | ₹-416 Cr | ₹-692 Cr | ₹1,162 Cr | — |
| Mar 2024 | ₹-163 Cr | ₹-68 Cr | ₹118 Cr | — |
| Mar 2025 | ||||
| Mar 2026 |
Register free to see 2 more years.
No dividend history available.
No corporate actions recorded.
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹4,51,075 Cr | 41.3 | 0.00% | +8.45% |
| Dr Reddys Laboratories Ltd | ₹1,11,310 Cr | 19.7 | +11.84% | +8.74% |
| Cipla Ltd | ₹1,15,638 Cr | 25.5 | +11.74% | -5.78% |
| Apollo Hospitals Enterprise Ltd | ₹1,16,201 Cr | 64.5 | 0.00% | +7.74% |
| Divis Laboratories Ltd | ₹1,79,486 Cr | 72.5 | 0.00% | +3.69% |
Create a free account to see institutional ownership snapshots.
Create a free account to view recent director and promoter trades.
Create a free account to view recent institutional deal activity.
Create a free account to view analyst estimate summaries.
Create a free account to view ESG risk and governance summaries.
Upgrade to view issuer ratings, instruments, outlooks, and rating history.
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.